Skip to main content

NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.

Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.

U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Prokaryotic Expression, Purification, and Reconstitution of Biological Activities (Antiprotease, Antitumor and Heparin-Binding) for Tissue Factor Pathway Inhibitor- 2

Published

Author(s)

C N. Rao, Prasad T. Reddy, D J. Reeder, Yonglin Liu, S M. Stack, W Kisiel, D T. Woodley

Abstract

We report the expression of tissue factor pathway inhibitor-2 (TFPI-2) (also known as PP-5, placental protein-5; MSPI, matrix-associated serine protease inhibitor) in E. coli as a 25 kDa non-glycosylated protein with a glycine substituted for aspartic acid at the amino terminus. High level expression of TFPI-2 was obtained with pRE1 expression vector under the transcriptional and translational controls of the lPL promoter and lcII ribosome-binding site, respectively, with ATG initiation codon. TFPI-2 was produced as inclusion bodies and accounted for 25 % to 30 % of the total E. coli proteins. The inclusion bodies containing TFPI-2 protein were solubilized with urea, sulfitolyzed, purified, and refolded through a disulfide interchange reaction. The refolded E. coli TFPI-2 inhibited plasmin with an inhibition constant (Ki) of 5 nM that is similar with the TFPI-2 expressed in a mammalian system using baby hamster kidney cells. Similar to TFPI-2 from the mammalian system, the refolded E.coli TFPI-2 bound heparin and also inhibited plasmin, regardless of whether the enzyme was in the fluid-phase or was bound to the membranes of HT-1080 fibrosarcoma cells. In addition, similar to TFPI-2 from the mammalian system, refolded E.coli TFPI-2 inhibited radiolabeled matrix degradation and Matrigel matrix invasion by HT-1080 fibrosarcoma cells and B16-F10 melanoma cells. Together, our results suggest that glycosylation is not essential for antiprotease, antitumor and matrix-binding activities of TFPI-2. Based on these collective data, we conclude that a biologically active non-glycosylated TFPI-2 can be produced in E.coli and that the protein can be produced in high-enough quantities to conduct in vivo studies for determination of the role of this inhibitor in tumor invasion and metastasis.
Citation
Biochemical and Biophysical Research Communications
Volume
276
Issue
3

Keywords

antiprotease activity, antitumor activity, glycosylation, matrix-binding activity, prokaryotic expression, protein refolding, serine protease inhibitors, TFPI-2

Citation

Rao, C. , Reddy, P. , Reeder, D. , Liu, Y. , Stack, S. , Kisiel, W. and Woodley, D. (2000), Prokaryotic Expression, Purification, and Reconstitution of Biological Activities (Antiprotease, Antitumor and Heparin-Binding) for Tissue Factor Pathway Inhibitor- 2, Biochemical and Biophysical Research Communications (Accessed October 17, 2025)

Issues

If you have any questions about this publication or are having problems accessing it, please contact [email protected].

Created October 4, 2000, Updated October 12, 2021
Was this page helpful?